Cubist Systematic Strategies’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-24,264
| Closed | -$393K | – | 3470 |
|
|
2024
Q3 | $393K | Buy |
24,264
+11,064
| +84% | +$130K | ﹤0.01% | 2314 |
|
|
2024
Q2 | $109K | Buy |
13,200
+6,886
| +109% | +$72.1K | ﹤0.01% | 2615 |
|
|
2024
Q1 | $93.4K | Buy |
+6,314
| New | +$85.1K | ﹤0.01% | 3281 |
|
|
2023
Q3 | – | Sell |
-10,124
| Closed | -$131K | – | 3830 |
|
|
2023
Q2 | $131K | Sell |
10,124
-4,676
| -32% | -$63.2K | ﹤0.01% | 2933 |
|
|
2023
Q1 | $195K | Sell |
14,800
-12,447
| -46% | -$198K | ﹤0.01% | 3246 |
|
|
2022
Q4 | $409K | Buy |
27,247
+10,277
| +61% | +$94.2K | ﹤0.01% | 3151 |
|
|
2022
Q3 | $200K | Buy |
16,970
+9,502
| +127% | +$129K | ﹤0.01% | 3763 |
|
|
2022
Q2 | $84K | Buy |
7,468
+5,638
| +308% | +$113K | ﹤0.01% | 4012 |
|
|
2022
Q1 | $55K | Sell |
1,830
-270
| -13% | -$7.31K | ﹤0.01% | 3359 |
|
|
2021
Q4 | $56K | Buy |
2,100
+1,439
| +218% | +$43.4K | ﹤0.01% | 3297 |
|
|
2021
Q3 | $24K | Buy |
+661
| New | +$26K | ﹤0.01% | 2879 |
|
|
2021
Q2 | – | Sell |
-3,615
| Closed | -$124K | – | 3067 |
|
|
2021
Q1 | $124K | Buy |
3,615
+968
| +37% | +$38.3K | ﹤0.01% | 2602 |
|
|
2020
Q4 | $93K | Sell |
2,647
-2,982
| -53% | -$86.3K | ﹤0.01% | 2416 |
|
|
2020
Q3 | $135K | Buy |
+5,629
| New | +$138K | ﹤0.01% | 2234 |
|
|
2019
Q4 | – | Sell |
-3,719
| Closed | -$70K | – | 2525 |
|
|
2019
Q3 | $70K | Buy |
3,719
+2,507
| +207% | +$51.8K | ﹤0.01% | 1989 |
|
|
2019
Q2 | $32K | Sell |
1,212
-6,187
| -84% | -$140K | ﹤0.01% | 2363 |
|
|
2019
Q1 | $190K | Sell |
7,399
-1,053
| -12% | -$24.1K | 0.01% | 1809 |
|
|
2018
Q4 | $194K | Buy |
8,452
+6,336
| +299% | +$179K | 0.01% | 1555 |
|
|
2018
Q3 | $68K | Sell |
2,116
-3,940
| -65% | -$118K | ﹤0.01% | 1662 |
|
|
2018
Q2 | $171K | Buy |
6,056
+4,037
| +200% | +$144K | 0.01% | 1407 |
|
|
2018
Q1 | $71K | Buy |
+2,019
| New | +$80.8K | ﹤0.01% | 1647 |
|
|
2017
Q4 | – | Sell |
-3,699
| Closed | -$94K | – | 2064 |
|
|
2017
Q3 | $94K | Buy |
+3,699
| New | +$90K | 0.01% | 1642 |
|
|
2017
Q1 | – | Sell |
-2,057
| Closed | -$49K | – | 1816 |
|
|
2016
Q4 | $49K | Sell |
2,057
-1,144
| -36% | -$32.8K | ﹤0.01% | 1583 |
|
|
2016
Q3 | $117K | Buy |
+3,201
| New | +$91.8K | 0.01% | 1431 |
|
|
2016
Q2 | – | Sell |
-1,350
| Closed | -$28K | – | 1853 |
|
|
2016
Q1 | $28K | Buy |
+1,350
| New | +$33.3K | ﹤0.01% | 1517 |
|
|
2015
Q4 | – | Sell |
-1,801
| Closed | -$44K | – | 1909 |
|
|
2015
Q3 | $44K | Buy |
+1,801
| New | +$53.7K | ﹤0.01% | 1730 |
|
|
2015
Q2 | – | Sell |
-2,216
| Closed | -$79K | – | 2011 |
|
|
2015
Q1 | $79K | Buy |
+2,216
| New | +$60.8K | ﹤0.01% | 1705 |
|
Other funds holding RIGL
AC
SCM
Cubist Systematic Strategies's RIGL Position: Q4 2024 in Review
Cubist Systematic Strategies sold out of Rigel Pharmaceuticals (RIGL) in Q4 2024, closing a stake of 24,264 shares — an estimated $393K sold.
Cubist Systematic Strategies first reported a position in RIGL in Q1 2015 and held it in 27 quarters. The position peaked at $409K in Q4 2022. 122 funds tracked by Wall St. Rank hold RIGL as of Q4 2024.
- Cubist Systematic Strategies reported no remaining Rigel Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
- Cubist Systematic Strategies sold 24,264 Rigel Pharmaceuticals shares in Q4 2024, an estimated $393K.
- Cubist Systematic Strategies first reported a position in Rigel Pharmaceuticals in Q1 2015 and held it in 27 quarters.
- Cubist Systematic Strategies's Rigel Pharmaceuticals position peaked at $409K in Q4 2022.
- 122 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2024.
Based on Cubist Systematic Strategies's 13F filing for Q4 2024, filed 14 Feb 2025.